GSK taps NCCN for cancer drug trials

- Last updated on GMT

GSK has awarded the National Comprehensive Cancer Network (NCCN) grants worth $4m to support trials involving ofatumumab and pazopanib.

The NCCN, a not-for-profit network of 21 US cancer research centres, said it would be testing the drugs as treatment for hematologic malignancies and solid tumors, respectively.

Jeffery Bloss, GSK’s VP of oncology drug development, said the funding “will help expand the research and knowledge base of GSK Oncology’s newer cancer therapies​.”

The two pharmaceuticals, branded as Arzerra and Votrient, are already approved by the US Food and Drug Administration (FDA) and generated around £13m (€15.5m) each last year according to GSK’s annual results.

Related news

Show more

Related products


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers